![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Novartis' Cosentyx Superior to Rival Stelara
Novartis' Cosentyx Superior to Rival Stelara
![Novartis logo](https://www.fdanews.com/ext/resources/test/Drug-Images2/Novartis.gif?t=1631046727&width=430)
March 11, 2016
In head-to-head trials, Novartis’ interleukin-17A inhibitor Cosentyx was more effective than Johnson & Johnson’s Stelara in retaining skin clearance in adults with moderate-to-severe plaque psoriasis.
Results from the 52-week study demonstrated that Cosentyx exhibited a superior rapid onset of action versus Stelara, but had a similar safety profile, Novartis said. Stelara recently was approved for the treatment of psoriatic arthritis and ankylosing spondylitis in the EU and U.S.
Upcoming Events
-
21Oct